HelioLiver LDT now available to order through Quest Diagnostics
Modern corporate skyline
Helio Genomics · Newsroom

Investor Relations

Recent press coverage and publications have highlighted Helio Genomics' market momentum in early cancer detection and diagnostics innovation.

Featured Coverage

Business Insider67.7M Monthly Visitors

Helio Genomics Announces New HelioLiver Access Through Quest

Business Insider covers the expanded provider access for HelioLiver beginning April 2026, detailing how healthcare providers with existing Quest accounts can order the blood-based liver cancer test through Quest's infrastructure of approximately 7,700 patient service centers and EHR integration.

Read the Coverage

In the Press

Helio Genomics' science, commercial milestones, and the Quest Diagnostics partnership have been covered across leading financial, industry, and clinical media.

Why AI Multiomics Will Replace Ultrasound in Liver Cancer ScreeningPodcast
Jul 14, 2026

Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening

Read on
Achyut Saroj: Seeing the Invisible – Closing the Liver Cancer Blind SpotVoices
May 24, 2026

Achyut Saroj: Seeing the Invisible – Closing the Liver Cancer Blind Spot

Read on
Revolutionary HelioLiver™ Test Outperforms Ultrasound for Early Hepatocellular Carcinoma DetectionNews
May 22, 2026

Revolutionary HelioLiver™ Test Outperforms Ultrasound for Early Hepatocellular Carcinoma Detection

Read on
Rural Healthcare Is Driving New Models for Earlier Detection and Better OutcomesIndustry
May 20, 2026

Rural Healthcare Is Driving New Models for Earlier Detection and Better Outcomes

Read on
Helio Genomics, Syneos Health Partner to Broaden Commercialization of Liver Cancer TestNews
May 19, 2026

Helio Genomics, Syneos Health Partner to Broaden Commercialization of Liver Cancer Test

Read on
Helio Genomics Announces Strategic Commercial Partnership with Syneos Health®Press Release
May 19, 2026

Helio Genomics Announces Strategic Commercial Partnership with Syneos Health®

Read on
FDA Expands Stelara Approval; Liver Cancer Blood Test; Pharmacotherapy for MASLDMedia Coverage
May 2026

FDA Expands Stelara Approval; Liver Cancer Blood Test; Pharmacotherapy for MASLD

Read on
HelioLiver Expands Access Through QuestNews
May 12, 2026

HelioLiver Expands Access Through Quest

Read on
Collaborating with the Rural Health Transformation Collaborative, Co-Chaired by MicrosoftNews
May 8, 2026

Collaborating with the Rural Health Transformation Collaborative, Co-Chaired by Microsoft

Read on
Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™ Over UltrasoundResearch
May 6, 2026

Landmark CLiMB Study Demonstrates Superior Sensitivity of HelioLiver™ Over Ultrasound

Read on
Bharat Tewarie: Giving Patients a “Real Fighting Chance” Against Liver CancerVoices
May 6, 2026

Bharat Tewarie: Giving Patients a “Real Fighting Chance” Against Liver Cancer

Read on
Helio Genomics partners with Syneos Health to accelerate liver cancer detectionPress Release
April 21, 2026

Helio Genomics partners with Syneos Health to accelerate liver cancer detection

Read on
Helio Genomics and Syneos Health PartnershipNews
April 21, 2026

Helio Genomics and Syneos Health Partnership

Read on
Helio Genomics Partners with Syneos Health to Enhance Liver Cancer Diagnostics with AI InnovationNews
April 21, 2026

Helio Genomics Partners with Syneos Health to Enhance Liver Cancer Diagnostics with AI Innovation

Read on
Expanding Early Detection of Hepatocellular Carcinoma With HelioLiverInterview
Apr 15, 2026

Expanding Early Detection of Hepatocellular Carcinoma With HelioLiver

Read on
Orange County Business Journal coverageNews
Apr 13, 2026

Helio Genomics Enters Full Launch with Quest Diagnostics

Read on
Yahoo! News coverageNews
Mar 30, 2026

Improving Early Detection and Treatment of Liver Cancer

Read on
FinanceWire coverageNews
Mar 30, 2026

Helio Genomics Announces New HelioLiver Access Through Quest

Read on
GlobalData coverageNews
Mar 30, 2026

Improving Early Detection and Treatment of Liver Cancer

Read on
Dealroom.co coverageNews
Mar 28, 2026

Quest Diagnostics to Offer Helio Genomics' AI-Powered Liver Cancer Blood Test Across US Network

Read on
Precision Medicine Online coverageNews
Mar 28, 2026

Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for US

Read on
Simply Wall St. News coverageNews
Mar 25, 2026

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on
Scope Forward (Becker's GI & Endoscopy) coverageNews
Mar 25, 2026

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
LiverRight coverageNews
Mar 25, 2026

Helio Genomics and Quest Diagnostics

Read on
Becker's ASC Review coverageNews
Mar 25, 2026

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
Brief Glance coverageNews
Mar 25, 2026

AI Blood Test for Liver Cancer Gains Massive Reach via Quest Deal

Read on
NewsBreak coverageNews
Mar 25, 2026

Quest Diagnostics to Offer Liver Cancer Blood Test

Read on
SAHM Capital coverageNews
Mar 22, 2026

How Investors May Respond to Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening and Boardroom Expertise

Read on
Helio Genomics to Make HelioLiver™ Accessible to Quest Diagnostics’ ProvidersPress Release
Mar 2026

Helio Genomics to Make HelioLiver™ Accessible to Quest Diagnostics’ Providers

Read on
Helio Genomics Supports American Liver Foundation Congressional Briefing on Liver CancerAdvocacy
2025

Helio Genomics Supports American Liver Foundation Congressional Briefing on Liver Cancer

Read on
American Liver Foundation Partners with Helio Genomics on the At-Home LiverTrace TestPartnership
2025

American Liver Foundation Partners with Helio Genomics on the At-Home LiverTrace Test

Read on
Helio Genomics Presents Three Abstracts at the 2025 Digestive Disease WeekPress Release
May 6, 2025

Helio Genomics Presents Three Abstracts at the 2025 Digestive Disease Week

Read on
Helio Presented CLiMB Trial Data and Methylation Model Score at AASLD and Virtual KOL EventResearch
Nov 26, 2024

Helio Presented CLiMB Trial Data and Methylation Model Score at AASLD and Virtual KOL Event

Read on
Helio’s Chief Medical Advisor to Present HelioLiver Data at the 2024 AASLD Annual MeetingPress Release
Nov 12, 2024

Helio’s Chief Medical Advisor to Present HelioLiver Data at the 2024 AASLD Annual Meeting

Read on
Methylation Model Score Presented as Top Abstract at the 2024 San Antonio Liver Cancer SymposiumResearch
Oct 14, 2024

Methylation Model Score Presented as Top Abstract at the 2024 San Antonio Liver Cancer Symposium

Read on
Helio Genomics CEO Justin Chen Li Selected to Join Leadership Board of Terasaki InstitutePress Release
Sep 24, 2024

Helio Genomics CEO Justin Chen Li Selected to Join Leadership Board of Terasaki Institute

Read on
Helio Genomics Appoints Eric Ariazi, Ph.D. as Chief Development OfficerPress Release
Aug 5, 2024

Helio Genomics Appoints Eric Ariazi, Ph.D. as Chief Development Officer

Read on
Helio Genomics Announces Separation from Laboratory for Advanced Medicine, a Cayman Holding CompanyPress Release
Jul 2, 2024

Helio Genomics Announces Separation from Laboratory for Advanced Medicine, a Cayman Holding Company

Read on
HelioLiver Dx Meets Coprimary and Secondary Study Endpoints in the CLiMB Trial at EASL 2024Press Release
Jun 10, 2024

HelioLiver Dx Meets Coprimary and Secondary Study Endpoints in the CLiMB Trial at EASL 2024

Read on
Helio Genomics to Showcase CLiMB Pivotal Trial Results at the EASL Congress 2024Press Release
May 6, 2024

Helio Genomics to Showcase CLiMB Pivotal Trial Results at the EASL Congress 2024

Read on
Helio Genomics Collaborates with UC Irvine to Study Multimodal Epigenetic Sequencing for Early Cancer DetectionResearch
Jan 18, 2024

Helio Genomics Collaborates with UC Irvine to Study Multimodal Epigenetic Sequencing for Early Cancer Detection

Read on
PM360 Announces Selections for 11th Annual Innovations IssueRecognition
December 2022

PM360 Announces Selections for 11th Annual Innovations Issue

Read on
Multimodal Analysis of cfDNA Methylation Sequencing Improves Early Colon Cancer DetectionResearch
October 2022

Multimodal Analysis of cfDNA Methylation Sequencing Improves Early Colon Cancer Detection

Read on
Helio Genomics Receives “Company of the Year” Award from Frost & SullivanAward
Oct 12, 2022

Helio Genomics Receives “Company of the Year” Award from Frost & Sullivan

Read on
Helio Genomics Recognized as Healthcare Technology of the YearAward
Oct 8, 2022

Helio Genomics Recognized as Healthcare Technology of the Year

Read on
Joyce Cheung Receives Women in Leadership AwardAward
Oct 8, 2022

Joyce Cheung Receives Women in Leadership Award

Read on
Dhruv Roy, Ph.D. Joins the Editorial Advisory Board of Onco’ZineRecognition
Aug 19, 2022

Dhruv Roy, Ph.D. Joins the Editorial Advisory Board of Onco’Zine

Read on
The AMA Approves a New Category I CPT® Code for the HelioLiver™ TestPress Release
Jul 5, 2022

The AMA Approves a New Category I CPT® Code for the HelioLiver™ Test

Read on
Helio Health Honored with Second Consecutive MedTech Breakthrough AwardAward
May 5, 2022

Helio Health Honored with Second Consecutive MedTech Breakthrough Award

Read on
HelioLiver™, an Innovative Liquid Biopsy Test for Early Liver Cancer Detection, Is Now Commercially AvailablePress Release
Dec 6, 2021

HelioLiver™, an Innovative Liquid Biopsy Test for Early Liver Cancer Detection, Is Now Commercially Available

Read on
Helio & Fulgent Announce Late-Breaking Positive HelioLiver™ Performance Data (ENCORE)Research
Nov 8, 2021

Helio & Fulgent Announce Late-Breaking Positive HelioLiver™ Performance Data (ENCORE)

Read on
Helio & Fulgent to Present New HelioLiver Data at The Liver Meeting® 2021Press Release
Nov 1, 2021

Helio & Fulgent to Present New HelioLiver Data at The Liver Meeting® 2021

Read on
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection TestsPress Release
Aug 9, 2021

Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests

Read on
Webcast: Helio Genomics Fireside Chat at the 2021 BTIG ConferenceWebcast
2021

Webcast: Helio Genomics Fireside Chat at the 2021 BTIG Conference

Read on
FUJIFILM Medical Systems and Helio Health Collaborate to Advance Early-Stage Liver Cancer ScreeningPress Release
May 12, 2021

FUJIFILM Medical Systems and Helio Health Collaborate to Advance Early-Stage Liver Cancer Screening

Read on
MedTech Breakthrough Honors Standout Innovation in the 2021 Awards ProgramAward
May 6, 2021

MedTech Breakthrough Honors Standout Innovation in the 2021 Awards Program

Read on
Helio Health and National Cancer Center Awarded Grant to Evaluate the Helio Liver Test in ChinaPress Release
Apr 28, 2021

Helio Health and National Cancer Center Awarded Grant to Evaluate the Helio Liver Test in China

Read on
Detect Cancer Early: Liquid Biopsy-Based ctDNA Methylation as a Promising Diagnostic ApproachVoices
Mar 20, 2020

Detect Cancer Early: Liquid Biopsy-Based ctDNA Methylation as a Promising Diagnostic Approach

Read on
Machine Learning with Cancer Methylation Signatures to Diagnose Colorectal CancerMedia Coverage
Jan 3, 2020

Machine Learning with Cancer Methylation Signatures to Diagnose Colorectal Cancer

Read on
ctDNA Methylation Profiles Power Effective Colorectal Cancer Diagnosis, Prognosis, and ScreeningMedia Coverage
Jan 3, 2020

ctDNA Methylation Profiles Power Effective Colorectal Cancer Diagnosis, Prognosis, and Screening

Read on
Circulating Tumor DNA Methylation Profiles May Aid in Colorectal Cancer Early DiagnosisMedia Coverage
Jan 2, 2020

Circulating Tumor DNA Methylation Profiles May Aid in Colorectal Cancer Early Diagnosis

Read on
AncestryDNA chief takes on liquid biopsy challenge; Thomas Lynch chairs former colleague’s cancer startupMedia Coverage
Nov 8, 2019

AncestryDNA chief takes on liquid biopsy challenge; Thomas Lynch chairs former colleague’s cancer startup

Read on
DNA Methylation Analysis for Early Detection of Various CancersInterview
May 29, 2019

DNA Methylation Analysis for Early Detection of Various Cancers

Read on
LAM’s research collaborators at UCSD prove that non-invasive blood testing may find liver cancer earlier and improve survival – San Diego Union TribuneMedia Coverage
Oct 9, 2017

LAM’s research collaborators at UCSD prove that non-invasive blood testing may find liver cancer earlier and improve survival – San Diego Union Tribune

Read on
Peer-Reviewed Science

Our Publications

For over a decade, Helio Genomics’ science has been published in the world’s most respected peer-reviewed journals — the research behind HelioLiver and the platform that powers it.

13+Years of published
science
9Peer-reviewed
publications
2Cancer indications
(HCC & CRC)
Molecular Cell2013

Genome-Wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates

A large-scale clinical study on cfDNA methylation in relation to aging and age-related diseases, where Helio’s science began.

Open Publication pubmed.ncbi.nlm.nih.gov
Proceedings of the National Academy of Sciences (PNAS)2017

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers

A large-scale clinical study across liver, colon, lung, and breast cancers, validating new DNA methylation markers.

Open Publication pnas.org
Nature Materials2017

Circulating Tumour DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma

A large-scale clinical study of cfDNA methylation markers in the detection of HCC.

Open Publication nature.com
Science Translational Medicine2020

Circulating Tumor DNA Methylation Profiles Enable Early Diagnosis, Prognosis Prediction, and Screening for Colorectal Cancer

A large-scale clinical study of cfDNA methylation markers in the detection of colorectal cancer (CRC).

Open Publication science.org
Nature Communications2021

Cellular Heterogeneity–Adjusted cLonal Methylation (CHALM) Improves Prediction of Gene Expression

An advanced bioinformatics algorithm that strengthens how methylation data predicts gene expression, part of the science behind Helio’s platform.

Open Publication nature.com
Hepatology Communications2022

A Multi-Analyte Cell-Free DNA–Based Blood Test for Early Detection of Hepatocellular Carcinoma

The ENCORE study. Clinical validation of the HelioLiver product for early HCC detection.

Open Publication pubmed.ncbi.nlm.nih.gov
Journal of HepatologyLatest · 2026

A Multi-Analyte cfDNA-Based Blood Test for Early Detection of Hepatocellular Carcinoma

The pivotal CLiMB trial. HelioLiver detected liver cancer earlier than ultrasound in a large, prospective US study of high-risk patients.

Open Publication journal-of-hepatology.eu
Molecular Cancer2023

Efficacy of a Cell-Free DNA Methylation-Based Blood Test for Colorectal Cancer Screening in a High-Risk Population: A Prospective Cohort Study

Clinical validation of the colorectal cancer screening test in a high-risk population.

Open Publication molecular-cancer.biomedcentral.com
Genome Medicine2024

Multimodal Epigenetic Sequencing Analysis (MESA) of Cell-Free DNA for Non-Invasive Colorectal Cancer Detection

A multimodal sequencing approach for non-invasive colorectal cancer detection.

Open Publication genomemedicine.biomedcentral.com
View All Publications